Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

NIH to study Pfiz­er's Paxlovid in long Covid as de­mand — and in­fec­tions — con­tin­ue to fall

Pfiz­er’s Paxlovid will be­come the first treat­ment stud­ied by the NIH for long Covid, the agency said Thurs­day.

The drug will be eval­u­at­ed as part …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.